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Purpose: The evaluation of anatomic and visual outcomes in macular hole cases treated with 
internal limiting membrane (ILM) peeling, brilliant blue (BB), and 23-gauge pars plana vitrec-
tomy (PPV).
Materials and methods: Fifty eyes of 48 patients who presented between July 2007 and 
December 2009 with the diagnosis of stage 2, 3, or 4 macular holes according to Gass Classi-
fication who had undergone PPV and ILM peeling were included in this study. Pre- and post-
operative macular examinations were assessed with spectral-domain optical coherence 
tomography. 23 G sutureless PPV and ILM peeling with BB was performed on all patients.
Results: The mean age of patients was 63.34 ± 9.6 years. Stage 2 macular hole was determined 
in 17 eyes (34%), stage 3 in 24 eyes (48%), and stage 4 in 9 eyes (18%). The mean follow-up 
time was 13.6 ± 1.09 months. Anatomic closure was detected in 46/50 eyes (92%), whereas, in 
four cases, macular hole persisted and a second operation was not required due to subretinal 
fluid drainage. At follow-up after 2 months, persistant macular hole was detected in one case 
and it was closed with reoperation. At 12 months, an increase in visual acuity in 41 eyes was 
observed, while it remained at the same level in six eyes. In three eyes visual acuity decreased. 
There was a postoperative statistically significant increase in visual acuity in stage 2 and 3 cases 
(P , 0.05), however, no increase in visual acuity in stage 4 cases was observed.
Conclusion: PPV and ILM peeling in stage 2, 3, and 4 macular hole cases provide successful 
anatomic outcomes, however, in delayed cases, due to photoreceptor loss, it has no effect on 
functional recovery. BB, used for clarity of ILM, may be beneficial due to its low retinal 
toxicity.
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Introduction
Tangential tractions on the vitreomacular interface are usually responsible for the 
development of idiopathic macular holes. The prevalence is 3.3/1000 and it shows a 
strong female predominance.1 In the past, it was known as a rare, untreatable disorder 
leading to central loss of vision. In 1991, Kelly and Wendel2 reported that idiopathic 
macular holes could be closed by vitrectomy and gas tamponade. With a better under-
standing of the pathogenesis of macular hole development and innovations in macular 
surgery, the rate of anatomical and functional success increased. One of the important 
developments in the surgical approach is peeling of the internal limiting membrane 
(ILM). Some authors have argued that ILM peeling has beneficial effects on the   surgical 
outcome,3,4 whereas others have stated that this approach does not affect surgical 
success,5,6 and may lead to complications by increasing the surgery duration.7,8Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The ILM is formed by Müller cell extensions and 
  functions as a kind of basal membrane between retina and 
vitreus, acting as a surface for glial cell proliferation. 
  Vitreoretinal interface changes due to cellular proliferation 
lead to ILM distortion and eventually to the development of 
epiretinal membrane (ERM), macular hole, and recurring 
macular edema.9 With the removal of the ILM, successful 
results may be obtained in surgical treatment of such vitreo-
retinal diseases. The most difficult aspect of surgery is due 
to the tight attachment of the ILM to the retina and its extreme 
thinness and transparent nature. To increase the visibility of 
the ILM, several vital dyes have been used recently. 
  Indocyanine green (ICG) and trypan blue have been used by 
many researchers in peeling of the ERM and ILM. There are 
different opinions on the amount and concentration of dye 
required, and exposure duration in the vitreous space. 
In many studies, because of intraretinal accumulation of ICG 
and its toxic effects on retinal pigment epithelium, visual 
field defects after surgery and possible optical nerve atrophy 
have been considered.8,10,11 Recently, brilliant blue (BB) has 
been used in preclinical studies as it has minimal toxic effect 
and provides effective membrane staining.9,12 In this study, 
the anatomical and visual outcomes of pars plana vitrectomy 
(PPV) and ILM peeling with BB in the treatment of idiopathic 
macular holes has been examined.
Methods and materials
Fifty eyes of 48 patients who had 23 G PPV and ILM peeling 
as a treatment for macular holes between July 2007 and 
December 2009 were retrospectively evaluated in the 
authors’ clinic. All patients underwent measurement of best-
corrected visual acuity and intraocular pressure, anterior 
segment and fundus examinations before surgery. The pos-
sible merits and risks of the treatment were explained to the 
patients, and informed consent was obtained from all patients 
in accordance with the Helsinki Declaration. Inclusion cri-
teria were: diagnosis using noncontact-lens biomicroscopy 
and optical coherence tomography (OCT) of stages 2, 3, and 
4 idiopathic macular hole according to the Gass classification. 
Exclusion criteria were: trauma history; previous macular 
surgery, rhegmatogenous retinal detachment together with 
macular hole; myopia higher than 10D; macular hole for 
more than 2 years; and previous retinal vessel disease. 
  Macular examination was performed before surgery and 1, 3, 
and 6 months after surgery using spectral OCT (Optovue 
Inc, Fremont, CA).
All patients had a 23 G transconjunctival three port pars 
plana vitrectomy. In four eyes having both macular hole and 
ERM, both ILM and ERM peeling were performed. 
To   visualize the ILM, 0.3 mL BB was used in all patients. 
At the end of the surgery, 16% C3F8 gas was injected into 
28 eyes (56%) and 18% C2F6 gas into 22 eyes (44%).
Follow-up time points included 1-day, 1-week, 1-month, 
3-month, and 6-month postsurgical evaluations and there-
after visits at 3-month intervals. Best-corrected visual 
acuity, intraocular pressure, and complications were 
recorded for each visit. Anatomical and functional outcomes 
of macular hole patients who underwent 23 G PPV and ILM 
peeling with BB were evaluated. Cases in different macular 
hole stages were compared in terms of anatomical and 
functional results.
Surgical technique
All operations were performed under local anesthesia. 
  Following the introduction of a 23 G infusion cannula at the 
inferotemporal site, other 23 G trochars were inserted at the 
superotemporal and superonasal quadrants. Imaging systems 
used were the Volk MiniQuad XL (Volk Optical Ltd, Mentor, 
OH) during vitrectomy and Volk Central Retina (Volk   Optical 
Ltd) during ILM peeling. After core vitrectomy, triamcinolone 
acetonide (Kenacort-A; Bristol Myers Squibb, New York, 
NY) was used to remove the posterior hyaloid. The posterior 
hyaloid was removed from the optic nerve head via high 
vacuum. Brilliant blue 0.3 mL (Fluoron Gmbh, Ludwigsfeld, 
Germany) was injected to the posterior pole via a 23 G dual-
bore cannula. After 60 seconds, peeling of the ILM was 
performed using a 23 G diamond-dusted membrane scraper 
(Synergetics Inc, Fort Collins, CO) and 23 G Eckardt end-
gripping forceps (DORC, Zuidland, The   Netherlands) for an 
area of at least 3 disc diameters. After liquid–air exchange, 
air–gas exchange was performed (16% C3F8 or 18% C2F6). 
None of the patients required sutures. Patients were asked to 
maintain a facedown position for 1 week.
Results
The patient group consisted of 33 (66%) female and 17 (34%) 
male subjects (mean age ± SD; 63.34 ± 9.6). Of these cases, 
31 were phakic (62%) and 19 were pseudophakic (38%). 
  Preoperative OCT examination revealed that, according to Gass 
classification, 17 eyes (34%) had stage 2 macular holes, 24 eyes 
(48%) had stage 3, and 9 eyes (18%) had stage 4. Four eyes 
with stage 2 macular holes also had an ERM. The mean 
  follow-up period after surgery was 13.6 ± 1.09 months. 
  Demographic characteristics of patients are given in Table 1.
Anatomic success was assessed by the closure of the hole 
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The hole was closed in 46 (92%) of the 50 eyes after surgery 
but not closed in 4 (8%) eyes. When postoperative OCT 
controls revealed that subretinal fluid had disappeared, there 
was no need for a second surgery. Hole persistence was 
observed in only one patient 2 months after the surgery and 
it was closed by reoperation. Figure 3 shows pre- and post-
operative third-month spectral OCT imaging of a patient with 
a stage 4 macular hole. Anatomic success was not different 
among the three groups.
The mean best-corrected visual acuity of all patients before 
surgery was 0.71 ± 0.25 logMAR. Postoperative mean best-
corrected visual acuity (and comparison with preoperative 
values) was obtained as: 0.48 ± 0.26 at 3 months (P , 0.05), 
0.52 ± 0.27 at 6 months (P , 0.05), 0.42 ± 0.30 at 9 months 
(P , 0.05), and 0.41 ± 0.31 at 12 months (P , 0.05). When 
assessed together, the final visits (at 12 months) demonstrated 
that visual acuity had increased in 41 eyes (82%), whereas, in 
6 eyes (12%), visual acuity remained unchanged. Because of 
recurrent macular holes, three cases showed a decrease in visual 
acuity. Two of these three cases had stage 4 macular holes, and 
one had a stage 3 macular hole. Best-corrected visual acuity 
results of patients before and after surgery are given in Figure 1 
and Table 2. When evaluated according to the stage of macular 
hole, in stage 2 patients, all measurements of visual acuity after 
surgery showed that it was significantly higher when compared 
with preoperative measurements (P , 0.05). Increase in visual 
acuity between 6 and 12 months after surgery was statistically 
significant due to cataract surgery (P , 0.05).
In stage 3 patients, preoperative visual acuity compared 
with postoperative 3-month scores showed an increase, but 
this was not statistically significant (P = 0.056). During the 
postoperative period, visual acuity reduced between months 
3 and 6 due to cataract development. In patients who underwent 
phacoemulsification after 6 months, visual acuity increased 
again. Therefore, comparisons of postoperative 9–12-month 
values showed significant increases (P , 0.05).
In contrast, in stage 4 patients, visual acuity scores of all 
time points after surgery failed to reach statistically signifi-
cant levels with respect to preoperative values. Visual acuity 
changes of these three groups are shown comparatively in 
Figure 2. An increase during the first month was not expected 
because of the gas endotamponade. Therefore, the first month 
visual acuity measurements were excluded from analysis. In 
22 phakic patients, visual acuity increased after cataract 
surgery at 6 months.
Table 1 Patient (n = 50) characteristics
gender
  Male (n) 17
  Female (n) 33
Age (years)
  Mean ± SD 63.34 ± 9.6
  range 39–82
Mean follow-up (months) 13.6 ± 1.09
Lens status before surgery
Phakic (n) 31
Pseudophakic (n) 19
Stage of macular hole
  Stage 2 17 (34%)
  Stage 3 24 (48%)
  Stage 4 9 (18%)
Abbreviations: n, number; SD, standard deviation.
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The mean preoperative visual acuity of stage 2 macular 
hole patients was higher than that of stage 3 or 4 patients. 
Consequently, the most prominent increase in visual acuity 
was observed in the stage 2 group after surgery. There was 
no significant difference between stage 2 and 3 macular hole 
patients in terms of anatomical and visual outcomes, but the 
functional successes of these two groups were significantly 
higher than those of stage 4 patients. Iatrogenic retinal tears 
developed in four patients during surgery and were success-
fully treated intraoperatively. In one patient, a nasal retinal 
tear developed near the optic nerve while removing the 
posterior hyaloid. One of the phakic cases had preoperative 
lens opacity and vitrectomy and phacoemulsification was 
performed together with intracapsular lens implantation. 
Postoperative controls revealed hypotonia in six patients, 
which regressed in 3 days.
Discussion
Since the first report of Kelly and Wendel2 on the treatment 
of macular holes by pars plana vitrectomy and gas   tamponade, 
anatomical and functional success rates have increased with 
developments in vitreoretinal surgery. Previous studies 
reported success rates over 90% after one session of 
surgery13,14 and anatomical success rates as high as 100% in 
stage 2 or the initial phase of stage 3 macular holes.15
In histopathological studies,16,17 various surgical 
approaches have been proposed based on the idea that col-
lagen-containing myofibroblasts and actin-containing cells 
in the structure of ILM and ERM may cause contraction and 
lead to hole formation or widening of an existing hole. Many 
studies18–21 have reported that ILM peeling increases anatomi-
cal and functional success in the treatment of macular hole, 
and during the late phases it reduces reformation of the hole. 
Kwok et al18 compared anatomical closure of stage 3 or 4 
holes in 40 patients with or without ILM peeling. Success 
rate was 89% in the ILM peeling group whereas it was 59% 
in the group without ILM peeling. The differences in ana-
tomical closure success may be due to stage differences of 
macular holes, inclusion of traumatic cases, high myopic 
eyes, and recurrent cases.
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Figure 2 Best-corrected visual acuity (BCVA) (logMAr) measurements of patients with stage 2, 3 and 4 macular hole after vitrectomy and brilliant blue–assisted internal 
limiting membrane peeling. Stages 2 and 3 patients showed significant improvements, whereas there was no significant change in stage 4 patients.
Abbreviations: preop, preoperative; postop, postoperative.
Table 2 Visual acuity (logMAr)
Macular  
hole stage
Preop Postop  
3 months
Postop  
6 months
Postop  
9 months
Postop  
12 months
Statistical  
significance (P)
2 0.60 ± 0.21 0.33 ± 0.13 0.35 ± 0.14 0.22 ± 0.12 0.20 ± 0.14 , 0.05
3 0.70 ± 0.24 0.47 ± 0.23 0.53 ± 0.25 0.43 ± 0.27 0.43 ± 0.27 , 0.05
4 0.89 ± 0.21 0.75 ± 0.28 0.78 ± 0.29 0.75 ± 0.32 0.75 ± 0.32  = 0.89
Abbreviations: preop, preoperative; postop, postoperative.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Although there is no consensus on the effects of ILM 
peeling on anatomical and functional success, publications 
stating that ILM peeling increases hole closure are in the 
majority.22,23 There are several opinions regarding which 
patients require ILM peeling. Previous studies have stated 
that ILM peeling should be considered especially in patients 
with a hole wider than 400 microns and that is chronic 
(6 months or longer), traumatic, or recurring.21–25 ILM peeling 
was reported to increase anatomical success and prevent 
reopening of the hole by decreasing ERM development.25,26 
Besides reports that suggest that ILM peeling increases 
anatomical success but not functional success,27 there are 
also reports that suggest functional outcomes are better in 
ILM peeling groups.18
In this study, ILM peeling was applied to all patients who 
underwent macular hole surgery. Anatomic closure was 
obtained in 46 (92%) of the 50 eyes, but the hole was not 
closed in four patients. Visual outcomes were significantly 
better in stage 2 or 3 patients than in stage 4 patients 
(P , 0.05). The most prominent postoperative visual acuity 
improvement was obtained in stage 2 patients. The authors 
consider that ILM peeling improved anatomical and func-
tional success rates in stages 2 and 3 patients whereas it had 
no effect on visual outcomes in stage 4 patients due to pho-
toreceptor loss.
Cataract development is the most prevalent complication 
of macular hole surgery in phakic eyes. In this study group, 
cataract development was observed in 23 (74%) of 31 patients 
due to an endotamponade application. Besides publications 
that report “early cataract surgery following macular hole 
surgery may increase the risk of re-opening of the hole,”28 
there are also studies that report no such risk.29,30 Therefore, 
in patients developing cataract, phacoemulsification surgery 
was performed at least 6 months after macular hole surgery 
to prevent a recurrence.
As the thin and semitransparent structure of the ILM 
complicates visualization during surgery, in patients with 
ILM peeling, there may be small asymptomatic paracentral 
scotomas, irregularity in nerve fiber layers, and retinal micro-
hemorrhages due to iatrogenic retinal trauma.31–36 Chromo-
vitrectomy has been developed as a method to improve ILM 
visibility, shorten the duration of surgery, and reduce iatro-
genic retinal trauma.36 Many dyes, such as indocyanine green 
(ICG), infracyanine green (IfCG), trypan blue (TB), BB, and 
triamcinolone acetonide (TA), are used to dye the ILM. Since 
ICG was first introduced for ILM peeling in macular hole 
surgery, several potential side effects have been noted.37,38 
Visual field defects, retinal pigment epithelium, and ganglion 
cell defects are among the most reported side effects.26,32,33 
Dose-dependent biochemical damage to the retinal pigment 
epithelium and ganglion cells, photo-oxidative cell damage 
due to the phototoxic properties of ICG, and retinal pigment 
epithelium damage due to hypoosmotic solution are consid-
ered responsible for ICG-mediated ocular toxicity.39–41 
Because of the potential toxic side effects of ICG in chro-
movitrectomy, other vital dyes with minimal toxicity have 
been tried.32,33,38,42 IfCG, unlike ICG, does not contain iodine, 
and it is widely thought that its toxicity to the retinal pigment 
epithelium is less than that of ICG.31 Triamcinolone acetonide 
was reported as both toxic43–45 and nontoxic46 to retinal pig-
ment epithelium in preclinical studies. In the authors’ opinion, 
there is an insufficient number of randomized clinical trials 
to make a conclusion. However, in some studies of TA-as-
sisted ILM peeling, it was found similar to ICG.43,47   
Another vital dye, TB, is recommended for ERM staining 
because of its high affinity for proliferation-dense intraocular 
tissues.48 Several preclinical studies with high-concentration 
TB reported toxic effects on tissue culture of retinal pigment 
epithelium.49,50 However, many other researchers claim that 
if it is used in lower concentrations, there will be no toxic 
effects.51,52
In this study, BB, a relatively new type of vital dye, was 
used to stain the ILM. It selectively dyes ILM and has no 
reported potential side effects or toxicity. The authors believe 
that it is the most effective alternative to ICG. Enaida et al9 
studied ICG on rats and found that low-dose ICG   administration 
A
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Figure 3 A representative patient with stage 4 macular hole. Preoperative (A) and 
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resulted in no retinal cell damage but high dose ICG led to 
morphological damage of retinal cells. In a rat study by 
Hisatomi et al and Enaida et al,53,54 low dose intravitreal BB 
administration caused no effects on retinal cells, but in higher 
doses electron microscopy revealed cyst formation in the 
inner layers of the retina. However, there was no apoptotic 
cell death. The authors of this present study think that bio-
logical adaptation to BB is better than to ICG. The use of BB 
is easier than ICG and TB because of its granular structure 
and easy dissolution in intraocular irrigation. It can be steril-
ized by a syringe filter. Additional surgical procedures such 
as fluid–air exchange are required before TB administration. 
Dissolving ICG is more difficult because of its structure. 
When compared with BB, higher concentrations of ICG are 
required to dye the ILM.12 In addition, BB is not a fluorescent 
dye, so its phototoxicity is lower than ICG. The authors of 
this study have observed intraretinal accumulation in post-
operative fundus fluorescein angiography of patients for 
whom ICG was used. Therefore, there may be long-term 
toxic effects.
Conclusion
ILM peeling in macular hole surgery provides beneficial 
effects on anatomical outcome, independent of disease stage. 
In terms of visual outcome, the highest success is obtained 
with stage 2 and 3 cases. It is not useful for stage 4 patients. 
Using BB for ILM peeling may provide beneficial effects 
with respect to retinal toxicity.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Schurmans A, Van Calster J, Stalmans P. Macular hole surgery with 
inner limiting membrane peeling, endodrainage, and heavy silicone oil 
tamponade. Am J Ophthalmol. 2009;147(3):495–500.
2.  Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. 
Results of a pilot study. Arch Ophthalmol. 1991;109(5):654–659.
3.  Kwok AK, Lai TY, Man-Chan W, Woo DC. Indocyanine green assisted 
retinal internal limiting membrane removal in stage 3 or 4 macular hole 
surgery. Br J Ophthalmol. 2003;87:71–74.
4.  Eckardt C, Eckardt U, Groos S, Luciano L, Reale E. Removal of the 
internal limiting membrane in macular holes. Clinical and morphological 
findings. Ophthalmologe. 1997;94(8):545–551. German.
5.  Smiddy WE, Feuer W, Cordahi G. Internal limiting membrane peeling 
in macular hole surgery. Ophthalmology. 2001;108(8):1471–1476.
6.  Benson WE, Cruikshanks KC, Fong DS, et al. Surgical management of 
macular holes: a report by the American Academy of Ophthalmology. 
Ophthalmology. 2001;108(7):1328–1335.
7.  Karacorlu M, Karacorlu S, Ozdemir H. Iatrogenic punctate chorioretin-
opathy after internal limiting membrane peeling. Am J Ophthalmol. 
2003;135(2):178–182.
8.  Rodrigues EB, Meyer CH, Farah ME, Kroll P. Intravitreal staining of 
the internal limiting membrane using indocyanine green in the treatment 
of macular holes. Ophthalmologica. 2005;219(5):251–262.
  9.  Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T. Morphological 
and functional damage of the retina caused by intravitreal indocyanine 
green in rat eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240(3): 
209–213.
  10.  Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, 
Kampik A. Indocyanine green-assisted peeling of the internal limiting 
membrane in macular hole surgery affects visual outcome: a clinico-
pathologic correlation. Am J Ophthalmol. 2002;134(6):836–841.
  11.  Maia M, Haller JA, Pieramici DJ, et al. RPE abnormalities after ILM 
peeling guided by ICG staining. Retina. 2004;24(1):157–160.
  12.  Enaida H, Hisatomi T, Hata Y, et al. Brilliant blue G selectively stains 
the internal limiting membrane. Retina. 2006;26(6):631–636.
  13.  Benson WE, Cruickshanks KC, Fong DS, et al. Surgical management 
of macular holes: a report by the American Academy of Ophthalmology. 
Ophthalmology. 2001;108(7):1328–1335.
  14.  Scott IU, Moraczewski AL, Smiddy WE, Flynn HW, Feuer WJ. Long 
term anatomic and visual acuity outcomes after initial anatomic success 
with macular hole surgery. Am J Ophthalmol. 2003;135(5):633–640.
  15.  Margherio RR, Margherio AR, Williams GA, Chow DR, Banach MJ. 
Effect of perifoveal tissue dissection in the management of acute idio-
pathic full-thickness macular holes. Arch Ophthalmol. 2000;118(4): 
495–498.
  16.  Yoshida M, Kishi S. Pathogenesis of macular hole recurrence and its 
prevention by internal limiting membrane peeling. Retina. 2007;27(2): 
169–173.
  17.  Yooh HS, Brooks HL Jr, Capone A Jr, L ’Hernault NL, Grossniklaus HE. 
Ultrastructural features of tissue removed during idiopathic macular 
hole surgery. Am J Ophthalmol. 1996;122(1):67–75.
  18.  Kwok AK, Lai TY, Yuen KS, Tam BS, Wong VW. Macular hole surgery 
with or without indocyanine green stained internal limiting membrane 
peeling. Clin Experiment Ophthalmol. 2003;31(6):470–475.
  19.  Foulquier S, Glacet-Bernard A, Sterkers M, Soubrane G, Coscas G. Study 
of internal limiting membrane peeling in stage-3 and -4 idiopathic macular 
hole surgery. French. J Fr Ophthalmol. 2002;25(10): 1026–1031.
 20.  Sheidow TG, Blinder KJ, Holekamp N, et al. Outcome results in macular 
hole surgery: an evaluation of internal limiting membrane peeling with and 
without indocyanine green. Ophthalmolgy. 2003;110(9):1697–1701.
  21.  Brooks HL Jr. Macular hole surgery with and without internal limiting 
membrane peeling. Ophthalmology. 2000;107(10):1939–1948.
  22.  Kuhn F. Point: To peel or not to peel, that is the question.   Ophthalmology. 
2002;109(1):9–11.
  23.  Hassan T, Williams GA. Counterpoint: To peel or not to peel: is that 
the question? Ophthalmology. 2002;109(1):11–12.
  24.  Margherio AR. Macular hole surgery in 2000. Curr Opin Ophthalmol. 
2000;11(3):186–190.
  25.  Kumagai K, Furukawa M, Ogino N, et al. Vitreous surgery with and 
without internal limiting membrane peeling for macular hole repair. 
Retina. 2004;24(5):721–727.
  26.  Haritoglou C, Gass CA, Schaumberger M, Ehrt O, Gandorfer A, 
Kampik A. Macular changes after peeling of the internal limiting 
membrane in macular hole surgery. Am J Ophthalmol. 
2001;132(3):363–368.
  27.  Al-Abdulla NA, Thompson JT, Sjaarda RN. Results of macular hole 
surgery with and without epiretinal dissection or internal limiting 
membrane removal. Ophthalmology. 2004;111(1):142–149.
  28.  Bhatragor P, Kaiser PK, Smith SD, Meisler DM, Lewis H, Sears JE. 
Reopening of previously closed macular holes after cataract extraction. 
Am J Ophthalmol. 2007;144(2):252–259.
  29.  Passemand M, Yakoubi Y, Muselier A, et al. Long-term outcome of 
idiopathic macular hole surgery. Am J Ophthalmol. 2010;149(1): 
120–126.
  30.  Hager A, Ehrich S, Wiegand W. Rate of reopening of macular holes 
following cataract operation. Ophthalmologe. 2007;104(5):388–392.
  31.  Farah ME, Maia M, Rodrigues E. Dyes in ocular surgery: principles for 
use in chromovitrectomy. Am J Ophthalmol. 2009;148(3):332–340.
  32.  Haritoglou C, Ehert O, Gass CA, Kristin N, Kampik A. Paracentral 
scotoma: a new finding after vitrectomy for idiopathic macular hole. 
Br J Ophthalmol. 2001;85(2):231–233.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1183
23 g pars plana vitrectomy in macular hole
  33.  Tsuiki E, Fujikawa A, Miyamura N, Yamada K, Mishima K, Kitaoka T. 
Visual field defects after macular hole surgery with indocyanine green-
assisted internal limiting membrane peeling. Am J Ophthalmol. 
2007;143(4):704–705.
  34.  Ito Y, Terasaki H, Takahashi A, Yamakoshi T, Kondo M, Nakamura M. 
Dissociated optic nerve fiber layer appearance after internal limiting 
membrane peeling for idiopathic macular holes. Ophthalmology. 
2005;112(8):1415–1420.
  35.  Christensen UC, Kroyer K, Thomadsen J, Jorgensen TM, la Cour M, 
Sander B. Normative data of outer photoreceptor layer thickness 
obtained by software image enhancing based on Stratus optical coher-
ence tomography images. Br J Ophthalmol. 2008;92(6):800–805.
 36.  Da Mata AP, Burk SE, Riemann CD, et al. Indocyanine green-assisted 
peeling of the retinal internal limiting membrane during vitrectomy surgery 
for macular hole repair. Ophthalmology. 2001;108(7):1187–1192.
  37.  Stanescu-Segall D, Jackson TL. Vital staining with indocyanine green: 
a review of the clinical and experimental studies relating to safety. Eye 
(Lond). 2009;23(3):504–518.
  38.  Ferencz M, Somfai GM, Farkas A, et al. Functional assessment of the 
possible toxicity of indocyanine green dye in macular hole surgery. Am 
J Ophthalmol. 2006;142(5):765–770.
  39.  Iriyama A, Uchida S, Yanagi Y, et al. Effects of indocyanine green on 
retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45(3):943–947.
  40.  Yip HK, Lai TY, So KF, Kwok AK. Retinal ganglion cell toxicity 
caused by photosensitizing effects of intravitreal indocyanine green 
with illumination in rat eyes. Br J Ophthalmol. 2006;90(1):99–102.
  41.  Jackson TL, Hillenkamp J, Knight BC, et al. Safety testing of indocya-
nine green and trypan blue using retinal pigment epithelium and glial 
cell cultures. Invest Ophthalmol Vis Sci. 2004;45(8):2778–2785.
  42.  Stanescu-Segall D, Jackson TL. Vital staining with indocyanine green: 
a review of the clinical and experimental studies relating to safety. Eye 
(Lond). 2009;23(3):504–518.
  43.  Nomoto H, Shiraga F, Yamaji H, et al. Macular hole surgery with 
  triamcinolone acetonide-assisted internal limiting membrane peeling: 
one year results. Retina. 2008;28(3):427–432.
  44.  Yu SY, Damico FM, Viola F, D’Amico DJ, Young LH. Retinal toxicity 
of intravitreal triamcinolone acetonide: a morphological study. Retina. 
2006;26(5):531–536.
  45.  Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal 
toxicity of intravitreal triamcinolone acetonide at high doses in the 
rabbit. Exp Eye Res. 2007;84(2):342–348.
  46.  Morrison VL, Koh HJ, Cheng L, Bessho K, Davidson MC, Freeman WR. 
Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. 
Retina. 2006;26(3):339–344.
  47.  Karacorlu M, Ozdemir H, Arf Karacorlu S. Does intravitreal triamci-
nolone acetonide assisted peeling of the internal limiting membrane 
affect the outcome of macular hole surgery? Graefes Arch Clin Exp 
Ophthalmol. 2005;243(8):754–757.
 48.  Rodrigues EB, Maia M, Meyer CH, Penha FM, Dib E, Farah ME. Vital   
dyes for chromovitrectomy. Curr Opin Ophthalmol. 2007;18(3): 
179–187.
  49.  Kwok AK, Yeung CK, Lai TY, Chan KP, Pang CP. Effects of trypan blue 
on cell viability and gene expression in human retinal pigment epithelial 
cells. Br J Ophthalmol. 2004;88(12):1590–1594.
  50.  Rezai KA, Farrokh-Siar L, Gasyna EM, Ernest JT. Trypan blue induces 
apoptosis in human retinal pigment epithelial cells. Am J Ophthalmol. 
2004;138(3):492–495.
  51.  Haritoglou C, Eibl K, Schaumberger M, et al. Functional outcome after 
trypan blue-assisted vitrectomy for macular pucker: a prospective, 
randomized, comparative trial. Am J Ophthalmol. 2004;138(1):1–5.
  52.  Beutel J, Dahmen G, Ziegler A, et al. Internal limiting membrane peeling 
with indocyanine green or trypan blue in macular hole sur-
gery: a   randomized trial. Arch Ophthalmol. 2007;125(3):326–332.
  53.  Hisatomi T, Enaida H, Matsumoto H, et al. Staining ability and biocom-
patibility of brilliant blue G: preclinical study of brilliant blue G as an 
adjunct for capsular staining. Arch Ophthalmol. 2006;124(4):514–519.
  54.  Enaida H, Hisatomi T, Goto Y, et al. Preclinical investigation of internal 
limiting membrane peeling and staining using intravitreal brilliant blue 
G. Retina. 2006;26(6):623–630.